Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Open Access
- 2 January 2023
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (2) , 468-472
Abstract
Daratumumab is approved as monotherapy and in combination regimens for the treatment of relapsed or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma [1,2]. The PAVO study (Cli...Keywords
Funding Information
- Janssen Research & Development, LLC (NCT02519452)
This publication has 13 references indexed in Scilit:
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trialThe Lancet Haematology, 2020
- Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Haematologica, 2020
- Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaBlood, 2019
- Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative studyBMC Cancer, 2019
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- Glucocorticoids in multiple myeloma: past, present, and futureAnnals of Hematology, 2018
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood, 2016
- Medical management of side effects related to CAR T cell therapy in hematologic malignanciesExpert Review of Hematology, 2016
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- International uniform response criteria for multiple myelomaLeukemia, 2006